Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

A key challenge in the development of precision medicine is defining the phenotypic consequences of pharmacological modulation of specific target macromolecules. To address this issue, a variety of genetic, molecular and chemical tools can be used. All of these approaches can produce misleading resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomenius, Michael J., Totman, Jennifer, Harvey, Darren, Mitchell, Lorna H., Riera, Thomas V., Cosmopoulos, Kat, Grassian, Alexandra R., Klaus, Christine, Foley, Megan, Admirand, Elizabeth A., Jahic, Haris, Majer, Christina, Wigle, Tim, Jacques, Suzanne L., Gureasko, Jodi, Brach, Dorothy, Lingaraj, Trupti, West, Kip, Smith, Sherri, Rioux, Nathalie, Waters, Nigel J., Tang, Cuyue, Raimondi, Alejandra, Munchhof, Michael, Mills, James E., Ribich, Scott, Porter Scott, Margaret, Kuntz, Kevin W., Janzen, William P., Moyer, Mikel, Smith, Jesse J., Chesworth, Richard, Copeland, Robert A., Boriack-Sjodin, P. Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983452/
https://www.ncbi.nlm.nih.gov/pubmed/29856759
http://dx.doi.org/10.1371/journal.pone.0197372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983452/
https://www.ncbi.nlm.nih.gov/pubmed/29856759
http://dx.doi.org/10.1371/journal.pone.0197372

Ejemplares similares